Federal Circuit Reverses JMOL of Invalidity of Teva’s Ajovy® Patents

On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment as a matter of law (“JMOL”) finding Teva’s asserted patent claims invalid for lack of written description and enablement in Teva Pharmaceuticals v. Eli Lilly & Co. (Appeal No. 24-1094) and reinstated the jury’s verdict finding the patents valid and infringed.... By: Venable LLP